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Class Action Suits Prompt Governmental Action to Examine Ritalin
Use and Regulation
Ann Chiumino

I. Introduction
In 1955, the Federal Food and Drug Administration approved the drug methylphenidate, otherwise
known as Ritalin, for use in treating general childhood
behavioral disorders.' Recently, in just under a decade,
the number of Ritalin prescriptions has increased by over
500%.2 Physicians, prompted by concerned parents and
teachers, increasingly diagnosed children with behavioral
problems and accordingly found that Ritalin alleviated
the children's symptoms. But when do child-like, rambunctious characteristics reflect a serious medical condition? More importantly, should parents, as consumers,
rely on drugs to counteract these behavioral problems?
Last year, parents of children diagnosed with
Attention Deficit Disorder ("ADD") and Attention Deficit
Hyperactivity Disorder ("ADHD") and who have taken
Ritalin filed three class action lawsuits in California, New
Jersey, and Texas against the drug's manufacturer, CibaGeigy/Novartis ("Ciba-Geigy"). 3 Although there are
significant diagnostic differences between the two disabilities, the suits involve both disorders. This article,
however, will only discuss the suits with regard to
ADHD. The suits specifically allege that Ciba-Geigy took
steps to promote and dramatically increase the sales of
Ritalin by:
1.
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actively promoting and supporting the
concept that a significant percentage of
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children suffer from a "disease" which
required narcotic treatment/ therapy;
2.

actively promoting Ritalin as the "drug of
choice" to treat children diagnosed with
ADD and ADHD;

3.

actively supporting groups such as Defendant Children and Adults with ADHD
("CHADD"), both financially and with
other means, so that such organizations
would promote and support (as a supposed neutral party) the ever-increasing
implementation of ADD/ADHD diagnoses as well as directly increasing
Ritalin sales;

4.

distributing misleading sales and promotional literature to parents, schools, and
other interested persons in a successful
effort to further increase the number of
diagnoses and the number of persons
prescribed Ritalin.4

As of April 22, 2001, two of the lawsuits have been dismissed, with the third still pending. Nevertheless, these
class actions demonstrate the need for an evaluation of
the drug Ritalin and its administration to children for
ADHD.
In order to be diagnosed with ADHD, children
must meet the following criteria, as set forth by the
Diagnostic and Statistical Manual of Disorders, Fourth
Edition ("DSM -IV"). 5 First, the child must demonstrate
six or more symptoms of either inattention or hyperactivity-impulsivity. 6 Symptoms of inattention include the
following:
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a)

b)
c)
d)

e)
f)

g)

h)
i)

often fails to give close attention to
details or makes careless mistakes in
schoolwork, work, or other activities;
often has difficulty sustaining attention
in tasks or play activities;
often does not seem to listen when
spoken to directly;
often does not follow through on instructions and fails to finish schoolwork,
chores, or duties in the workplace (not
due to oppositional behavior or failure to
understand instructions);
often has difficulty organizing tasks and
activities;
often avoids, dislikes, or is reluctant to
engage in tasks that require sustained
mental effort (such as schoolwork or
homework);
often loses things necessary for tasks or
activities (e.g. toys, school assignments,
pencils, books, or tools);
is often easily distracted by extraneous
stimuli;
is often forgetful in daily activities.7

Symptoms of hyperactivity include the following:
a) often fidgets with hands and feet or squirms in
seat;
b) often leaves seat in classroom or in other situations in which remaining seated is expected;
c) often runs about or climbs excessively in situations in which it is inappropriate;
d) often has difficulty playing or engaging in
leisure activities quietly;
e) is often "on the go" or often acts as if "driven
by a motor";
8
f) often talks excessively.
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Lastly, symptoms of impulsivity include the following:
g) often blurts out answers before questions have
been completed;
h) often has difficulty awaiting turn;
i) often interrupts or intrudes on others (e.g.
butts into conversations or games).9
Children must exhibit these symptoms for at least
six months and the impairment from the symptoms must
be present in at least two different settings (in school, at
home, etc.). 1° Moreover, there needs to be clear evidence
of "clinically significant impairment in social, academic,
or occupational functioning."" Lastly, the symptoms
must not occur exclusively during the course of a developmental disorder, schizophrenia, or other psychotic
disorder, and the symptoms should not be better accounted for by another mental disorder.12 After a physician confirms the aforementioned symptoms in a child
and diagnoses him with ADHD, the next step is to determine proper treatment.
Ritalin is a nerve stimulant drug that physicians
3
primarily prescribe to children who suffer from ADHD.1
The drug produces an increase in neural activity that, in
most people, results in increased motor activity. 4 In
hyperactive children, however, Ritalin produces the
opposite result and the children become calmer.15 Most
children are then better able to concentrate and focus
their attention on school. Another important advantage
6
of Ritalin is that it is effective almost immediately.
Despite these advantages, the drug has a multitude of
possible side effects, not limited to the following: insomnia, nervousness, loss of appetite, abdominal pain,
weight loss, extensive bruising, and abnormally low red
and white blood cell counts. 7 The medical evidence in
Witherspoon v. Ciba-Geigy suggested that children could
even develop Tourette's Syndrome from taking Ritalin.' 8
Although most long-term side effects are unknown, one
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well-known side effect is the possibility of developing an
addiction to Ritalin or other similar stimulant drugs. 9
Despite the unavoidable risks of taking Ritalin, physicians continue to recommend and prescribe this drug to
children diagnosed with ADHD, presumably because the
benefits of the drug tend to outweigh the possible
harms.2 °
For a multitude of reasons, Ritalin has been a
controversial drug for nearly 30 years. Additional issues
surrounding the drug include effectiveness of the drug,
school administration of the drug, amount of proper
dosage, and, most recently, Ritalin fraud and abuse in
schools and on the street. The totality of these controversies has led to the formation of several different groups of
supporters and dissenters of the drug. On the one side
are those parents and professionals who do not believe
that ADHD is an actual condition and, therefore, want
physicians to discontinue prescribing Ritalin when children exhibit the alleged symptoms. At this extreme, these
advocates want the drug taken off of the market completely. On the other side, also represented by parents
and professionals, are those who believe ADHD to be a
serious illness and that Ritalin is the safest, easiest, and
often the only treatment for a child with ADHD. To date,
neither side has prevailed in its advocacy.
This Article will explore the merits and weaknesses of each set of arguments in light of the recent class
action lawsuits that plaintiffs brought against Ciba-Geigy.
Specifically, this Article will present congressional testimony from various witnesses regarding the diagnosis of
ADHD, as well as Ritalin treatment for the condition.
Lastly, this Article will demonstrate that Congress's
proposed bill relating to the prescription and administration of psycho-stimulants in children, if enacted, would
be a productive step in combating the over-prescription
of Ritalin.

384

Loyola Consumer Law Review

Volume 13, Number 4 2001

II. Current Litigation Regarding Ritalin
Since its approval in the 1950's, Ritalin has been a
topic of controversy for numerous reasons. The first
controversy is whether physicians should prescribe
mood-altering psychotropic medication to children.
Likewise, there are a multitude of potential side effects
attributable to the drug. Finally, many parents do not
want their children stigmatized for having to take medication regularly. For these reasons, parents, educators,
and physicians have questioned whether Ritalin is an
appropriate treatment for children.
In 1986, for example, plaintiffs in Witherspoon
brought a lawsuit against Ciba-Geigy alleging that the
corporation failed to warn Ritalin users of the potential
side effect of Tourette's Syndrome. 21 On appeal, the plaintiffs mistakenly argued that the trial court erred in refusing to admit the defendants' revised warning label that
was issued subsequent to the child's prescription of the
medication.22 Because the plaintiffs had brought forth a
strict liability claim, rather than negligence, the Tennessee
Appellate Court found no error.23 The court stated that
based on the medical and scientific knowledge available
at the time the child began taking the drug, the old warning label had been sufficient and it accordingly found for
24
Ciba-Geigy.
The issue in the three class action lawsuits is
whether Ciba-Geigy conspired and colluded to promote
the diagnosis of ADHD (as well as ADD) in an effort to
expand the market for Ritalin.25 Other named defendants
include Children and Adults with Attention Deficit/
Hyperactivity Disorder ("CHADD'), which allegedly
accepted donations and contributions from Ciba-Geigy/
Novartis so that the organization would help increase
sales and use of Ritalin.26 A third named defendant is the
American Psychiatric Association due to its involvement
in establishing the diagnosis of ADHD. 27 The plaintiffs
additionally allege that Ciba-Geigy distributed mislead-
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ing sales and promotional materials to parents, schools,
28
and others in order to increase sales.

III. Evidence to Support a Ban on Ritalin Use
In response to these lawsuits and in consideration
of ongoing studies involving Ritalin and other psychiatric medications, Congress recognized a need for further
investigation regarding the use of this drug. In September 2000, Congress held hearings before the Subcommittee on Oversight and Investigations, under the Committee on Education and the Workforce in the wake of the
lawsuits.
A. A Physician's Perspective on Ritalin Use
Appearing before members of the Subcommittee,
Dr. Peter Breggin, Director of the International Center for
the Study of Psychiatry and Psychology, testified regarding the fallacy of ADHD and the over-prescription of
Ritalin. 29 Dr. Breggin presented evidence illustrating the
similarities between the effects of Ritalin and cocaine on
the brain, thus suggesting the addictive nature of the
drug.30 Secondly, Dr. Breggin analyzed the three diagnostic categories of ADHD: hyperactivity, impulsivity, and
inattention. 31 He emphasized the correlation between
disruptive behavior in classrooms and these characteristics. 3 2 Dr. Breggin asserted that the diagnosis of ADHD
was aimed at controlling disruptive, but not diseased,
children in the classroom.33 Likewise, he stated that there
were no statistics to confirm a biological basis for
ADHD. 34 Lastly, Dr. Breggin stated that physicians tended
to prescribe stimulant drugs in general as a quick, effective alternative to examining actual problems in the
child's life. 5 Instead of analyzing why a child is restless
or disobedient, the parents or schools simply choose to
give the child a pill so that he will be "drugged into a
more compliant or submissive state."'
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Although Dr. Breggin's views are extreme in that
he believes that the ADD/ADHD diagnoses were concocted by an organization that needed a market for its
new drug, he supports his conclusions with scientific
evidence. First, he states that there is no known scientific
evidence in the brain of ADHD, which means that the
37
diagnosis is based entirely on behavioral characteristics.
Second, Dr. Breggin notes that the three different bases
for diagnosis of ADHD (hyperactivity, impulsivity, and
inattention) are extremely subjective because children
naturally exhibit these characteristics. Physicians must
therefore make the difficult determination of what is
"normal" behavior and what is a medical condition.38
Lastly, he recommends that those who actually observe
these diagnostic characteristics, primarily teachers and
parents, should try to be the persons who should decide
what treatment is appropriate for these children.39 Ideally,
the physicians who write the prescriptions for Ritalin
should be able to observe the children's behavior in order
to assess whether drugs are in the best interest of the
children. Instead, physicians usually spend a relatively
short amount of time with the children and try to learn
more about their daily behavioral characteristics from
their parents and teachers. Based on these subjective
observations by parents and teachers, doctors must then
decide the appropriateness of prescribing Ritalin.
B. Other Harmful Effects of Ritalin
Although the Ciba-Gaigy lawsuits prompted the
Congressional hearings, other topics of concern were
addressed in addition to the actual validity of ADHD as a
medical condition. Numerous studies indicate, for example, that between 1990 and 2000, the production and
subsequent use of Ritalin has increased by 500-800%. 40
Another issue that Congress has addressed is the growing prevalence of Ritalin abuse among school-age children, as well as college students and adults. Because
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Ritalin is a powerful and somewhat addictive nerve
stimulant drug, the Drug Enforcement Administration
("DEA") has classified it in the Schedule II of the Controlled Substances Act ("CSA") category in 1971.41 Other
Schedule II drugs, which are classified as such due to
their high abuse potential and dependence profile, include cocaine, barbiturates, and most opiates.42 Reports
show that to achieve the desired effect, abusers crush
Ritalin pills into a fine powder and snort the substance;
other evidence shows children dissolving the pills and
injecting the liquid like heroin.43
Although few states or local governments have
brought lawsuits regarding Ritalin abuse by children or
college students, several sources verify the prevalence of
abuse occurring. The DEA, for example, conducted a
study in 1998-1999 that examined abuse of methylphenidate as shown by poison control data, emergency room
data, and high school surveys.' Additionally, the DEA
stated that from January 1990 to May 1995, methylphenidate ranked in the top ten most frequently reported
controlled drugs stolen.45 These statistics reflect thefts
from facilities that are registered with the DEA to carry
the drugs.46 Unfortunately, the DEA does not require
schools to be register and report how much Ritalin they
have, even though schools often keep children's bottles
for daily dosages.47 Therefore, precise statistics identifying theft from unregistered facilities, as well as from
private individuals, are impossible to ascertain.
Unfortunately, an alarming number of schoolteachers and administrators have been caught stealing
Ritalin from school facilities. In March 2000, the Tennessee Court of Appeals in Lannom v. Board of Education
affirmed the termination of a tenured teacher who was
caught on videotape stealing pills from a student's prescription bottle. 48 Over the course of two years, the school
experienced eight incidents in which Ritalin was missing
from a student's bottle, even though the pills were stored
in a locked area of a school office.49 With help from the
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local police department, the principal installed a surveillance camera in the office where the pills were kept and
replaced the Ritalin with baby aspirin in order to appres The plaintiff was thus apprehended
hend the offender.5
and terminated after a hearing, with no formal charges
brought against him."
News reports also indicate that Ritalin abuse
occurs even when interested parties do not file
lawsuits.52 In October 2000, the principal of an elementary
school in Orem, Utah spent 30 days in jail for replacing a
student's Ritalin with sugar pills. 53 In that situation, not
only was the principal allegedly abusing the drug, but he
was also endangering the treatment and health of a
student by depriving the student of his medication.
Likewise, in Indiana, a school nurse was fined $1,300 and
ordered into treatment after stealing Ritalin and other
drugs from a locked cabinet. 54 Although few cases have
actually been litigated, the DEA evidence supports the
contention that for every abuse instance that ends up in
the news, there are numerous unreported incidents that
do not become public.55
In response to the growing abuse of Ritalin, as
well as other psycho-stimulants, Henry Hyde (R-IL),
Chairman of the Committee on the Judiciary asked the
General Accounting Office ("GAO") to undertake a study
of Ritalin abuse in schools.56 This request came just two
weeks before Dr. Breggin's testimony on September 29,
2000. This report, however, has not yet been published
and there are no news releases indicating when the
report might be available. Additionally, Rep. Hyde supported legislation requiring the states to certify the existence of guidelines for prescription use of Ritalin on
school premises.57 Likewise, Representative Bob Schaeffer
proposed House Resolution 459 earlier last year that
among other provisions urged Congress to "exercise its
oversight responsibilities and conduct hearings concerning the provision for school children of prescriptions for
psychotropic drugs." S The Bill attracted 24 co-sponsors
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and was referred to a House subcommittee, but was not
59
enacted before the end of the last Congressional term.
The last section of this article will explore this proposal to
greater lengths.

IV. Affirmative Support for Ritalin Use in
Children
Now that Congress and some physicians are
beginning to investigate and closely scrutinize whether
Ritalin is appropriate for the escalating amount of children taking the drug, concerned parents and physicians
are coming forth and expressing their support for the
drug. The supporters first emphasize the positive effects
of the drug, insisting that the medication has helped their
children and patients with ADHD live more normal
lives. 6 They also adamantly oppose the contention that
ADHD is a condition originally created by a drug company to boost sales of a product.6 ' While little biochemical
evidence demonstrates why Ritalin, a nerve stimulant,
helps hyperactive children slow down and focus, dissenters have a difficult time disputing the observations of
grateful parents and teachers who have witnessed their
children's behavioral improvements after they began
taking the drug.62
On May 16, 2000, Ms. Mary Robertson, the past
President of CHADD, submitted testimony regarding
Ritalin to the Early Childhood, Youth and Families
Subcommittee. 63 Robertson stated that when her son was
diagnosed with ADHD, she vowed that she would not
treat his condition with medication. 64 Instead, she sought
evaluations from a neurologist, an allergist, a hearing
specialist, an ophthalmologist, a pediatrician, and numerous psychologists and psychiatrists. 65 Her son was also
exposed to various treatment therapies, such as allergy
shots, dietary changes, behavior management, accommodations at school, and interventions.' After conservative
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treatments failed and her son came home from school
crying because he was always getting in trouble and not
remembering how to spell, Robertson decided to put her
son on Ritalin.67 She described the change in her son as
"watching a scene from Dr. Jekyll and Mr. Hyde. 68
Although she acknowledged the inherent drawbacks of
the drug and recounted her son's ultimate struggle
through elementary and middle school, she urged the
Subcommittee not to disregard the helpful effects that
69
Ritalin has had on millions of children.
That same day, Ms. Francisca Jorgenson, a Special
Educator for the Arlington County School System also
testified as to the benefits of drug treatment.70 Jorgenson
emphasized that while environmental and behavioral
modifications should be an integral part of treating a
child with special needs, medication often needs to be
part of a child's treatment.7' She stated, that conservative
treatment alone is not enough for some children and that
"Ritalin is an academic and social necessity."7 Like
Robertson, Jorgenson witnessed the dramatic improvements in the numerous children with whom she has
worked .73
While educators and schools have been among the
most vehement supporters of the use of Ritalin to treat
ADHD, some parents have found it necessary to take
action against schools that refuse to administer the drug
to their children. In Davis v. Francis Howell School District
and DeBord v. Board of Education of the Ferguson-Florissant
School Dist., parents brought lawsuits against their
children's schools because the school nurse refused to
administer Ritalin. 74 1n both cases, the nurses stated that
because the daily amount of medication that the child
was prescribed exceeded the recommended dosage in the
Physician's Desk Reference, school policy forbade them
from administering any dosages at school. 75 Although the
court did not rule on the propriety of dispensing the drug
at schools, it did not find that the school discriminated
against the children for not dispensing the medication in
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alternate ways due to the high dosage.76 Together, the two
cases collectively demonstrate that while schools generally support use of Ritalin, they do not want to face
liability for any potential problems stemming from
overmedication of the children. 77
Likewise, parents often look to Ritalin for their
children to avoid the stigma of attending remedial
classes. This stigmatism is a valid concern for parents and
their children who suffer from ADHD. For example, if a
teacher gives an ADHD student the extra attention
needed to help him focus in a regular class, other students may openly question the student's abilities. Additionally, the teachers are not always able to devote equal
attention to other students; they must often modify their
classrooms to accommodate children with special
needs. 7 When choosing between transferring the child to
a classroom where he can receive the attention he needs
or giving the child medication, most parents would
prefer to keep the child in the regular classroom and
endure the inconvenience and drawbacks of medication,
especially when the families have exhausted conservative
treatments.79

V. Congressional Support for a Middle Ground
Approach to Ritalin
Considering the two aforementioned extremes,
those who support the use of Ritalin and those who
discount its effects, a middle-ground approach consisting
recognizing ADHD and strictly regulating the distribution of medication would be the most advantageous
solution to the controversy. This solution would involve
participation of the government, the school systems,
physicians, and parents of children with ADHD. Several
interested parties have expressed support for this middle
ground approach, which would include greater government involvement and additional research as to the
actual scientific effects of the drug.
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Dr. Lawrence Diller, a behavioral pediatrician,
submitted testimony on May 16, 2000, to Congress regarding the use of Ritalin.80 Dr. Diller recognized the
dramatic increase in use of the drug in the past ten years
and partially attributed the increase to greater pressure
put on children to achieve and be successful at earlier
ages.81 He noted, however, that the actual improvements
in behavior that Ritalin causes in ADHD children are
virtually the same improvements as those exhibited in
any other child or adult who took the drug. 2 In other
words, if Ritalin can bring about behavioral improvements in every sector of the population, then just because
a child responds to the drug does not necessarily mean
that he suffers from ADHD, or that Ritalin is the most
appropriate treatment. Although Dr. Diller stated that
stimulant drugs could be effective for "a limited number
of children and adults who are compromised in any
situation," he discredited the idea that improved diagnostic guidelines could help remedy the overuse of
Ritalin. 3 Instead, Dr. Diller took a broader stance and
concluded that parents and doctors must change the way
they treat the children's behavior, personality, and performance problems. 4 Although the change in focus could
dramatically decrease the amount of children on psychotropic medication, Dr. Diller offers no means of achieving
these changes in the societal attitude, and his testimony
falls short of a practical solution to the problems he
outlines.
Congressional representatives, however, recognized the need for governmental action and recently
addressed the Ritalin controversy. The House Resolution
459 ("H. Res. 459") is a good model of a preliminary
effort by Congress to take a more active, educated role in
the regulation of stimulant drugs used for therapeutic
purposes. 5 First, the resolution proposes that Congress
conduct hearings regarding the prescription of psychotropic drugs in order to gather information on how the
drug is currently being used.8 6 As demonstrated, Con-

Volume 13, Number 4 2001

Loyola Consumer Law Review

393

gress did conduct preliminary hearings that brought
forth information from various physicians, teachers, and
parents; H. Res. 459 would investigate this issue even
further. 7 Although the testimony presents potentially
useful information, the many disparities in the various
opinions illustrate the need for increased research. Accordingly, Congress's second proposition is that the
National Academy of Sciences "study the effects of prescription psychotropic drugs on the academic achievement and behavior of children" to remedy the lack of
scientific evidence that is currently known about the
effects of the drug. 8
Additionally, H. Res. 459 calls for the federal
government to support state and local education agencies
with respect to their "conclusions and resolutions" regarding the prevalence of children taking psychotropic
medication. 9 Likewise, the resolution encourages school
personnel to use academic and classroom management
techniques to work with children who have behavioral or
attention problems (essentially, symptoms of ADHD).90
This step is crucial in reducing the number of children on
Ritalin because teachers and school administrators are
often the persons who most often observe the childrens'
behaviors and subsequently recommend that parents
should give their children Ritalin. 91
Lastly, the proposed legislation urges increased
communication among parents, educators, and medical
professionals with regard to the effects of psychotropic
drugs on school children, both behaviorally and
academically.92 By working together, these individuals
might be able to focus more on childrens' needs and less
on the differences in their points of view. More specifically, the Resolution proposes a focus on regulations
pertaining to administering and prescribing the drug to
schoolchildren, in the hopes of combating both overdiagnosis as well as potential abuse. 93
H. Res. 459 is a positive, comprehensive step
towards increased regulation and more careful prescrip-
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tion of Ritalin, as well as any other psycho-stimulant that
may replace it in the future. This piece of legislation is a
good model of how government can exercise its authority
over public education in a way that brings together
interested parents, teachers, and physicians in an effort to
help the children who suffer from behavioral disorders.
Additionally, the language of the resolution is appropriate because it does not promote an outright ban on the
use of medication to treat children's behavioral problems.
Rather, H. Res. 459 recognizes the need for increased
scientific research and general supervision of the drug,
while at the same time encouraging greater use of behavioral management in classrooms. H. Res. 459 effectively
seeks to reach a much-needed middle ground between
those who zealously oppose drug use and those who
believe that Ritalin is the best answer for children with
behavioral problems.

VI. Conclusion
As major consumers of Ritalin, parents, on behalf
of their children, need to be aware of the potential harms
surrounding the medication. Likewise, parents should
also realize that they often have options apart from
medicating their children, so that their children can
maintain normal lives. Parents should also be aware that
more and more people are beginning to abuse Ritalin, a
practice that could endanger their children as well as
individuals who take the substance illegally. Most importantly, as House Resolution 459 advocates, parents must
work along with teachers and physicians to insure that
children receive the best treatment possible for their
particular illnesses. Hopefully, with the help of the government, physicians, concerned teachers and parents,
children will receive improved diagnoses and treatment
for whatever behavioral problems they might have.

Volume 13, Number 4 2001

Loyola Consumer Law Review

395

Endnotes
1. Shankar Vedantam, A Symptom of the Times? ADD, Ritalin Focus of
Suits, PHIL.. INQ., Dec. 11, 2000, available at http://www.parkinsonsinformation-exchange-network-online.com/drugdb/083.htm.
2. Hearing on Ritalin Use Among Youth; Examining the Issues and
Concerns, Subcommittee on Early Childhood, Youth and Families,
Comm. on Education and the Workforce, 106th Cong. 109, (2000)
(statement of Terrence Woodworth, Drug Enforcement Agency,
Deputy Director of the Office of Diversion Control) 2000 WL 644334,
available at http://www.dea.gov/pubs/cngrtest/ct5l600.htm.
[hereinafter DEA]. This figure reflects the increase in Ritalin use
between 1990 and 2000.
3. Jennifer L. Reichart, Class Action Suits Target Ritalin, 36-DEC Trial
89, 89-90 (Dec. 2000). The cases were filed as follows: Vess v. CibaGeigy Corp., No. 00-CV-1839 (S.D.Cal. filed Sept. 13, 2000); Dawson
v. Ciba-Geigy Corp., No. BER-L-7774-00 (N.J., Bergen County Super.
Ct. filed Sept. 13, 2000); Hernandez v. Ciba-Geigy Corp., No. 2000051888D (Tex., Cameron County Dist. Ct. filed May 1, 2000).
4. Ritalin Fraud, (2000), availableat www.ritalinfraud.com. [hereinafter
Fraud]. These claims specifically are those from the Texas lawsuit, but
represent the general allegations of all three suits.
IV-R (Am. Psychiatric Ass'n et al. eds., 4th ed. 1994) [hereinafter DSM-IVI.
5. DIAGNOSTIC AND STATISTICAL MANUAL OF DISORDERS

6. Id.
7. Id.
8. Id.
9.Id.
10. Id.
11. Id.
12. Id.
13. James O'Leary, An Analysis of the Legal Issues Surrounding the
Forced Use of Ritalin: Protectinga Child's Right to "Just Say No", 27 NEW
ENG. L. REV. 1173, 1178 (1993).

396

Loyola Consumer Law Review

Volume 13, Number 4 2001

14. Id.
15. Id. at 1179.
16. Id. at 1175.
17. Therese Powers, Race for Perfection: Children's Rights and Enhancement Drugs, 13 J.L. & HEALTH, 141, 144 (1998-99); See also Fraud,supra
note 4, at 1.
18. Witherspoon v. Ciba-Geigy Corp., 1986 Tenn. App. LEXIS 2773.
Tourette's syndrome is a central nervous system disorder characterized by uncontrollable motor and phonic tics that wax and wane in
severity. Plaintiffs alleged that their child, Kent, began exhibiting
symptoms of Tourette's syndrome shortly after he began taking the
drug. The symptoms subsequently ceased immediately after he
discontinued taking Ritalin, which made them aware of the possible
connection.
19. Powers, supra note 17, at 145.
20. O'Leary, supra note 13, at 1179.
21. Witherspoon, 1986 Tenn. App. LEXIS, at *2.
22. Id. at *4.
23. Id.
24. Id. With regard to the issue of whether Ritalin caused the
Tourette's Syndrome, the Tennessee Appellate Court also held that
the trial court did not err when it relied on the medical and scientific
knowledge available at the time of the trial.
25. Fraud,supra note 4, at 1.
26. Id.
27. Id.
28 Id.
29. Peter R. Breggin, Peter Breggin MD Testifies Before Congress on
Ritalin, (Sept. 29, 2000), available at http://www.breggin.com/
congress.html. [hereinafter Breggin].

Volume 13, Number 4 2001

Loyola Consumer Law Review

397

30. Id.
31. Id.
32. Id.
33. Id.
34. O'Leary, supra note 13, at 1179. This article supports Dr. Breggin's
assertion that there is no scientific evidence to support the connection between Ritalin and ADHD.
35. Id.
36. Id.
37. Id.
38. Richard Welke, LitigationInvolving Ritalin and the Hyperactive
Child, 1990 DET. C. L. REV. 125, 134 (Spring 1990) [hereinafter Litigation]. This article presents the "Diagnostic Criteria for Attention
Deficit Disorder with Hyperactivity" as it was listed in the 1980
Diagnostic and Statistical Manual of Mental Disorders (DSM) Third
(Ill). These characteristics are still presently the elements of ADHD,
although the DSM-IV is now the current manual.
39. Breggin, supra note 29.
40. Kristen L. Aggeler, Is ADHD a "Handy Excuse"? Remedying Judicial
Bias Against ADHD, 68 UMKC L. REV. 459, 463 (Spring 2000) [hereinafter Handy Excuse]; DEA, supra note 2, at 1.
41. DEA, supra note 2, at 1.
42. Id.at 1-2.
43. Id.
44. DEA, supra note 2, at 8.
45. Id. at6.
46. Id.
47. Id.

398

Loyola Consumer Law Review

Volume 13, Number 4 2001

48. Lannom v. Bd. of Educ., No. MI 1999-00137-COA-R3-CV, 2000 WL
243971, at *1 (Tenn. Ct. App. March 6, 2000).
49. Id. at *2.
50. Id.
51. Id.
52. Karen Thomas, Stealing, Dealing and Ritalin, USA TODAY, Nov. 27,
2000, at 3, availableat http: / /www.usatoday.com /life/health/child/
lhchi2l5.htm [hereinafter Stealing].
53. Id.
54. Id.
55. DEA, supra note 2, at 6.
56. News Advisory for the Committee on the Judiciary, Hyde Wants
Study of Ritalin Abuse in Schools, (Sept. 14, 2000), availableat http://
www.house.gov/judiciary/na091400.htm. [hereinafter Hyde].
57. Id. at 1.
58. H.R. 459, 106th Cong. (2000), availableat http://thomas.loc.gov/
cgi-bin/bdquery/z?dl06:.h.res.00459:html.
59. House HearingHighlights Extremes of Ritalin Controversy, (Oct. 8,
2000), available at http://www.specialednews.com/storyarchive/
1000/ritalinhearingl008.htm. [hereinafter House Hearing].
60. Mary Robertson, Testimony of Mary Robertson, Lexington, KY,
Respectfully Submitted to the U.S. House of Representatives Early Childhood, Youth and Families Subcommittee, (May 16, 2000), availableat
http: / /edworkforce.house.gov/ hearings/ 106th/ecyf/ritalin51600/
robertson.htm. [hereinafter Robertson].
61. Id.
62. Jillene Magill-Lewis, Psychotropicsand Kids: Use of Drugs in
Treating ADHD Sets Off New Debate About Finding the Right Therapy for
Children, 2000 WL 9185300 (2000) [hereinafter Psychotropics].
63. Robertson, supra note 59. Note that Ms. Robertson's testimony
actually occurred before the California and New Jersey lawsuits had

Volume 13, Number 4 2001

Loyola Consumer Law Review

399

even been filed. Congress had therefore already begun to examine
the use of the drug.
64. Id.
65. Id.
66. Id.
67. Id.
68. Id.
69. Id.
70. Francisca Jorgensen, Testimony of Ms. Jorgensen, (May 16, 2000),
availableat http: / /www.house.gov/edworkforce/hearings/ 106th/
ecyf/ritalin5l600/jorgensen.htm. [hereinafter Jorgensen]. Again, Ms.
Jorgensen's testimony came before two of the lawsuits were filed.
71. Id.
72. Id.
73. Id.
74. Davis v. FrancisHowell Sch. Dist., 138 F.3d 754 (8th Cir. 1998);
DeBord v. Bd. of Educ. of the Ferguson-FlorissantSch. Dist., 126 F.3d 1102
(8th Cir. 1997).
75. Davis, 138 F.3d at 755; DeBord, 126 F.3d at 1104.
76. Davis, 138 F.3d at 756; DeBord, 126 F.3d at 1105. Note that these
cases were bought forth on a Title II claim, based on alleged discrimination against the children for their disabilities.
77. Davis, 138 F.3d at 756; DeBord, 126 F.3d at 1105.
78. Jorgensen, supra note 69.
79. Robertson, supra note 62.
80. Dr. Lawrence Diller, Testimony of Dr. Diller, (May 16, 2000),
availableat http: / /www.house.gov/ed-workforce/hearings/ 106th/
ecyf/ritalin51600/diller.htm. [hereinafter Diller].

400

Loyola Consumer Law Review

Volume 13, Number 4 2001

81. Id.
82. Id.
83. Id.
84. Id.
85. H.R. 459, 106th Cong. (2000), available at http://thomas.loc.gov/
cgi-bin/query/C?c106:. / temp/-c1065pJMXF.
86. Id.
87. See Breggin supra note 18; see also Robertson supra note 51.
88. H.R. 459, 106th Cong. (2000) available at http://thomas.loc.gov/
cgi-bin/query/C?c106:./temp/-cl065pJMXF.
89. Id.
90. Id.
91. Deborah Pryce, Testimony of the Honorable Deborah Pryce (R-OH15), (May 16, 2000), availableat http://house.gov/ed-workforce/
hearings/ 106th /ecyf/ritalin51600/pryce.html. [hereinafter Pryce].
92. Id.
93. Id.

Volume 13, Number 4 2001

Loyola Consumer Law Review

